Market Signal Briefing

After a turbulent week in the crypto markets, Bitcoin (BTC) has regained momentum, climbing back above $103,000 on Friday — marking a 2% rise in the past 24 hours. Earlier in the day, BTC had dipped near the $99,000 level following a steep drop from over $110,000 earlier in the week. The recovery offers some relief to bullish investors after the digital asset’s sharp two-day plunge of nearly 10%.

Altcoins also joined the rebound. Ethereum (ETH) traded at $3,431, up around 4%, while XRP ($2.32) and Solana (SOL) at $162 gained roughly 5%. Dogecoin (DOGE) and Cardano (ADA) led the surge with impressive jumps of 12% and 9%, respectively. Despite these upticks, analysts view the current upswing as a short-covering rally following a week of heavy selloffs across the sector.

Macroeconomic data added another layer of intrigue to Friday’s market movements. The University of Michigan’s Consumer Sentiment Index fell sharply to 50.3 in November from 53.6 in October, matching lows seen during previous recessions. While long-term inflation expectations eased slightly to 3.6%, consumers still expressed growing concerns about weakening job markets and financial strain.

The unexpected drop in consumer sentiment could influence the U.S. Federal Reserve’s next move. After signaling a hawkish stance last week, policymakers may need to reconsider delaying further rate cuts at their December meeting. Meanwhile, pressure is mounting on Congress to address the ongoing government shutdown as economic uncertainty deepens.

As investors look ahead, Bitcoin’s ability to sustain momentum above the $100,000 mark could determine short-term market sentiment. For now, the crypto market is finding cautious optimism amid broader financial turbulence.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

XRP has taken a sharp downturn over the past week, currently trading around $2.18 — a price last seen in late 2024 or early 2025. This decline effectively wipes out months of gradual progress and signals a significant shift in market sentiment. After several failed breakout attempts and a prolonged period of consolidation, XRP has fallen back into the range that once fueled its previous bull run, but this time under far less optimistic conditions.

The recent drop can be attributed to the breakdown of a rising wedge formation, a bearish continuation pattern that typically forecasts further declines. Every recovery effort has been capped by the 200-day exponential moving average (EMA), now acting as strong resistance between $2.50 and $2.60. Additionally, the 20-day, 50-day, and 100-day moving averages are trending downward, confirming continued selling pressure across the market.

Trading volume has surged during sell-offs, highlighting that major investors are still offloading positions. The Relative Strength Index (RSI) sits at 36, indicating near-oversold conditions, but this does not guarantee an immediate rebound. Without a clear demand zone beneath current levels, XRP risks revisiting the $2.00 or even $1.80 range if bearish momentum persists.

Although the same zone triggered a major rally in late 2024, market conditions have changed dramatically. Investor confidence has weakened, liquidity has declined, and Ripple’s on-chain activity — including transaction volumes and active payments — has slowed. While a short-term bounce could occur due to oversold conditions, sentiment remains cautious. Unless buying interest returns soon, XRP may continue retracing its steps, revisiting past lows before any meaningful recovery begins.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Strategy Inc., the world’s first and largest Bitcoin treasury company, has successfully completed its initial public offering of Series A Perpetual Stream Preferred Stock (STRE Stock), raising approximately $715 million (€620 million). The company plans to use the proceeds to acquire additional Bitcoin and strengthen its working capital, reinforcing its leadership in corporate Bitcoin accumulation.

Announced on November 6, 2025, the offering includes 7.75 million shares priced at €80 each, with settlement expected on November 13, pending standard closing conditions. After underwriting and offering expenses, Strategy expects net proceeds of around €608.8 million ($702.2 million), based on an exchange rate of €1.00 to $1.1534. The offering was upsized from an earlier target of $405 million following strong institutional investor demand, as confirmed by CEO Michael Saylor.

The joint book-running managers include Barclays, Morgan Stanley International plc, Moelis & Company, SG Americas Securities, TD Securities (USA), Canaccord Genuity, and StoneX Financial. Each STRE share offers a 10% annual dividend, payable quarterly from December 31, 2025. Missed payments will accrue quarterly at compounding rates, starting at 11% and increasing by 1% per quarter to a maximum of 18% annually, until all owed dividends are fulfilled.

In the event of deferred dividends, Strategy intends to liquidate portions of its STRK, STRD, and MSTR Class A stock to cover payments.

On the same day, the company announced the purchase of 397 Bitcoin worth $45.6 million, bringing its total holdings to 641,205 BTC, valued at $64.2 billion. Despite Bitcoin’s recent dip to $100K, Strategy maintains an impressive 26.1% year-to-date yield, surpassing NVIDIA in the top U.S. corporate treasury rankings. The company remains the only one in the top 10 holding Bitcoin as its primary reserve asset.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XRMost (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved Teva is committed to truly understanding and empowering individuals living with TD to help improve their TD and regain their independence
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to reductions in the severity of involuntary movements and improvements in patient-reported quality of life. The data were presented at the 2025 Neuroscience Education Institute Fall Congress, taking place November 6 – 9, 2025 in Colorado Springs, Colorado.

"The silent struggle of tardive dyskinesia, with its relentless, involuntary movements, can deprive patients of their quality of life and independence—real-world findings are so critical to inform how we innovate and improve the everyday lives of individuals living with this disease,” said Stacy Finkbeiner, Senior Medical Director, Movement Disorders & Psychiatry at Teva. “These data articulate patient experience and further validate clinical research showing how AUSTEDO or AUSTEDO XR can help people living with tardive dyskinesia improve their symptoms while maintaining their mental health, something we care deeply about in our mission at Teva to improve the lives of patients.”

The interim analysis of the IMPACT-TD Registry, a Phase 4 study, evaluated 27 adults with TD treated with AUSTEDO or AUSTEDO XR after a three-month period using IMPACT-TD PRO, a 30-question scale measuring patient-reported impact across 5 key areas. The study included patients with common comorbid psychiatric disorders, such as bipolar disorder (41%), anxiety disorder (37%), depression (26%), and schizophrenia (19%), reflecting a diverse, real-world patient population.

Key results revealed:

Patient-reported meaningful improvement after three months on AUSTEDO or AUSTEDO XR across several areas, including speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%).At three months, the total motor score on the Abnormal Involuntary Movement Scale (AIMS) showed a mean decrease of -2.9, indicating a notable reduction in the severity of uncontrolled movements consistent with what was previously seen in pivotal trials.Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their underlying mental health condition remained stable or improved based on the Patient Global Impression of Severity (PGIS) scale. While Part A of the IMPACT-TD Registry demonstrated the broad impact TD has on individuals beyond physical movements, these initial findings from Part B reflect patient-reported improvements in everyday tasks like speaking, eating, and other activities of daily living as a result of movement reduction with AUSTEDO or AUSTEDO XR.

About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.1,2,3

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets
AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE
AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington’s disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Hauppauge, NY: Nova Science Publishers. 2013:235-258.Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Accessed May 4, 2023.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.

So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the MoonLake Immunotherapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Enterprise Products Partners (EPD - Free Report) reported $12.02 billion in revenue for the quarter ended September 2025, representing a year-over-year decline of 12.7%. EPS of $0.61 for the same period compares to $0.65 a year ago.

The reported revenue represents a surprise of -4.53% over the Zacks Consensus Estimate of $12.59 billion. With the consensus EPS estimate being $0.67, the EPS surprise was -8.96%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Enterprise Products performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

NGL Pipelines & Services net - NGL fractionation volumes per day: 1636 millions of barrels of oil per day versus 1719.13 millions of barrels of oil per day estimated by two analysts on average.NGL Pipelines & Services net - Fee-based natural gas processing per day: 7454 millions of barrels of oil per day compared to the 7711.24 millions of barrels of oil per day average estimate based on two analysts.NGL Pipelines & Services net - NGL pipeline transportation volumes per day: 4694 millions of barrels of oil per day compared to the 4562.86 millions of barrels of oil per day average estimate based on two analysts.Natural Gas Pipelines & Services net - Natural gas transportation volumes per day: 21,027.00 BBtu/D versus the two-analyst average estimate of 20,722.93 BBtu/D.Petrochemical Services net - Butane isomerization volumes per day: 123 millions of barrels of oil per day compared to the 120.61 millions of barrels of oil per day average estimate based on two analysts.Petrochemical Services net - Propylene fractionation volumes per day: 119 millions of barrels of oil per day versus 113.58 millions of barrels of oil per day estimated by two analysts on average.Petrochemical Services net - Octane enhancement and related plant sales volumes per day: 41 millions of barrels of oil per day versus 38.03 millions of barrels of oil per day estimated by two analysts on average.NGL Pipelines & Services net - Equity NGL production per day: 225 millions of barrels of oil per day compared to the 218.7 millions of barrels of oil per day average estimate based on two analysts.Gross operating margin- NGL Pipelines & Services: $1.3 billion versus $1.37 billion estimated by two analysts on average.Gross operating margin- Crude Oil Pipelines & Services: $371 million versus the two-analyst average estimate of $377 million.Gross operating margin- Natural Gas Pipelines & Services: $339 million versus the two-analyst average estimate of $402.33 million.Gross operating margin- Petrochemical & Refined Products Services: $370 million compared to the $343.04 million average estimate based on two analysts.View all Key Company Metrics for Enterprise Products here>>>

Shares of Enterprise Products have returned -0.9% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

-

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Driven Brands Holdings Inc. (NasdaqGS: DRVN).

On August 2, 2023, the Company disclosed 2Q2023 earnings that missed expectations, including disappointing results for its Glass business segment, that was at least “several quarters” behind on its integration of the businesses it had acquired, its Car Wash segment that suffered from increased exposure to “intensified competitive intrusion” that negatively impacted demand, as well as its Paint and Collision segments. As a result of delays in its integration of its acquired auto glass businesses and the faltering performance of its car wash businesses, the Company slashed its full-year earnings guidance for fiscal 2023, despite prior affirmations of the same.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information, violating federal securities laws. Recently, the court presiding over the case denied the Company’s motion to reconsider its prior decision denying the defendants’ request to dismiss the case, allowing the case to further continue.

KSF’s investigation is focusing on whether Driven’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Driven shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit us at https://www.ksfcounsel.com/cases/nasdaqgs-drvn/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

More News From Kahn Swick & Foti, LLC

Back to Newsroom

Q3: 2025-11-06 Earnings SummaryEPS of $1.76 beats by $0.63

 |

Revenue of

$507.21M

(21.10% Y/Y)

beats by $33.88M

Intercorp Financial Services Inc. (IFS) Q3 2025 Earnings Call November 7, 2025 9:00 AM EST

Company Participants

Luis Castellanos López-Torres - CEO & GM
Michela Ramat - Chief Financial Officer
Gonzalo Basadre
Carlos Tori Grande - Chief Executive Officer

Conference Call Participants

Ivan Peill
Yuri Fernandes - JPMorgan Chase & Co, Research Division
Daniel Mora - CrediCorp Capital, Research Division

Presentation

Operator

Good morning, and welcome to Intercorp Financial Services Third Quarter 2025 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] It is now my pleasure to turn the call over to Ivan Peill from InspIR Group. Sir, you may begin.

Ivan Peill

Thank you, and good morning, everyone. On today's call, Intercorp Financial Services will discuss its third quarter 2025 earnings. We are very pleased to have with us Mr. Luis Felipe Castellanos, Chief Executive Officer, Intercorp Financial Services; Ms. Michela Casassa, Chief Financial Officer, Intercorp Financial Services; Mr. Carlos Tori, Chief Executive Officer, Interbank; Mr. Gonzalo Basadre, Chief Executive Officer, Interseguro; Mr. Bruno Ferreccio, Chief Executive Officer, Inteligo.

They will be discussing the results that were distributed by the company yesterday. There is also a webcast video presentation to accompany the discussion during this call. If you didn't receive a copy of the presentation or the earnings report, they are now available on the company's website, ifs.com.pe. Otherwise, if you need any assistance today, please call InspIR Group in New York on (646) 940-8843.

I would like to remind you that today's call is for investors and analysts only. Therefore, questions from the media will not be taken. Please be advised that forward-looking statements may be made during this conference call. These do not account for future economic circumstances, industry conditions, the company's financial performance or financial results. As such, statements made are based on several assumptions and factors that could

Recommended For You

November 07, 2025 6:09 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS" or "ADSs") of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP's media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273637

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –

– Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session -

RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company developing therapies to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that clinical data for lorundrostat were presented at the American Society of Nephrology (ASN) Kidney Week 2025. Findings included a late-breaking oral presentation of the Phase 2 Explore-CKD trial and recognition of the pivotal Phase 3 Launch-HTN trial in the “Best of the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine (NEJM)” session.

“The presentations at ASN Kidney Week demonstrated the breadth and strength of lorundrostat’s clinical program. As previously announced, the compelling results from multiple trials in this program have positioned us well for the planned filing of a New Drug Application to the FDA in the fourth quarter of 2025 or the first quarter of 2026,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “In Explore-CKD, lorundrostat reduced both blood pressure and albuminuria in participants with chronic kidney disease. We are pleased that the significant and consistent blood pressure reduction previously reported with lorundrostat in the Launch-HTN trial was selected for the “Best of JAMA” presentation at ASN’s Kidney Week 2025. With consistent benefits across blood pressure and kidney outcomes, lorundrostat is uniquely positioned to address the growing burden of cardio-renal-metabolic disease.”

Late-breaking presentation on the Explore-CKD trial (NCT06150924) of lorundrostat 25 mg once daily added to standard-of-care therapy, including sodium-glucose cotransporter-2 (SGLT2) inhibitors, demonstrated statistically significant and clinically meaningful reductions in blood pressure and albuminuria in participants with uncontrolled hypertension and CKD at four weeks of treatment. The trial met its primary endpoint, showing a reduction of 9.3 mmHg in automated office systolic blood pressure (AOSBP), and a placebo adjusted reduction of 7.5 mmHg (p-value=0.0024) at week four. Lorundrostat also achieved a reduction in spot urinary albumin-to-creatinine ratio (UACR), a marker of kidney protection, of 25.6% placebo-adjusted reduction (p=0.0015) at week four.

In Explore-CKD, lorundrostat demonstrated a favorable safety and tolerability profile. Serious adverse events occurred in two participants (3%) during lorundrostat treatment and none on placebo. Discontinuations due to treatment-emergent adverse events occurred in two participants (3%) during the lorundrostat treatment period and one participant (2%) during the placebo treatment period.

“These results are important because they show that lorundrostat, when added to standard-of-care therapy, reduced both blood pressure and proteinuria in patients with hypertension and chronic kidney disease,” said Dr. Matthew Weir, Director of the Division of Nephrology at the University of Maryland Medical Center, Professor of Medicine at the University of Maryland School of Medicine, and a scientific consultant to Mineralys Therapeutics. “The parallel reductions in systolic blood pressure and albuminuria underscore the potential of lorundrostat to improve cardio-renal outcomes in this high-risk population.”

In addition, the pivotal Phase 3 Launch-HTN trial was recognized in ASN’s “Best of JAMA and NEJM” session following publication earlier this year in JAMA. Lorundrostat demonstrated a statistically significant 16.9 mmHg absolute reduction in systolic blood pressure (SBP) at week 6 (9.1 mmHg placebo-adjusted, p<0.0001) and a 19 mmHg reduction in SBP at week 12 (11.6 mmHg placebo-adjusted, p<0.0001) in participants with uncontrolled and resistant hypertension, with a blood pressure-lowering effect observed as early as 2 weeks.

“Across trials, lorundrostat showed efficacy in diverse and difficult-to-treat patient groups, including those with confirmed uncontrolled and resistant hypertension, chronic kidney disease, obesity, and in Black or African American participants. Launch-HTN results demonstrated that lorundrostat lowers blood pressure with a persistent, clinically meaningful benefit a full 24-hours following administration,” said Dr. Manish Saxena, MBBS, Hypertension Specialist and Clinical Co-Director at William Harvey Heart Centre, Barts Health NHS Trust and QMUL. “Taken together with Advance-HTN and Explore-CKD, these results show lorundrostat has broad clinical potential across some of the most challenging patient populations.”

Lorundrostat continues to be evaluated in the ongoing Transform-HTN open-label extension study, which is assessing long-term safety and durability of response. The Company also completed enrollment in Explore-OSA, the first trial to evaluate lorundrostat in participants with hypertension and moderate-to-severe obstructive sleep apnea (OSA). Lorundrostat is the only ASI being studied to address both apnea-hypopnea index (AHI) and nighttime systolic blood pressure in this population, with data anticipated in the first quarter of 2026.

About Explore-CKD

The Explore-CKD trial (NCT06150924) was a randomized, double-blind, placebo-controlled, two-period, two-sequence (2x2) crossover trial. This Phase 2 trial was designed to evaluate BP reduction and safety of 25 mg QD lorundrostat when added to background treatment with an ACEi or ARB and an SGLT2 inhibitor for the treatment of hypertension in subjects with CKD subjects with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m2 and albuminuria (UACR of 200-5,000 mg/g). The primary efficacy endpoint of the trial was change from baseline in systolic BP at week four in the active versus placebo treatment period. Exploratory endpoints included change from baseline in UACR and eGFR at week four in the active versus placebo treatment period.

About Chronic Kidney Disease (CKD)

CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), an estimated 1-in-7 (approximately 37 million) U.S. adults have CKD, and approximately 22 million people in the United States are living with both hypertension and CKD. The relationship between these conditions is tightly linked: sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening BP control. When CKD is present in patients with hypertension, the risk of cardiovascular disease and mortality rises significantly.

Emerging evidence points to dysregulated aldosterone as a key driver of both diseases. Excess aldosterone promotes sodium retention, vascular inflammation, and fibrosis, contributing to both uncontrolled BP and kidney injury. Despite the availability of existing therapies, a significant proportion of patients remain uncontrolled or undertreated. Early detection and targeted interventions that address underlying mechanisms, such as aldosterone dysregulation, may offer the potential to slow CKD progression, reduce cardiovascular risk, and improve long-term outcomes. Without effective management, CKD can advance to kidney failure, requiring dialysis or transplantation.

About Launch-HTN

Launch-HTN (NCT06153693) was a global, randomized Phase 3 double-blind, placebo-controlled trial of adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Participants were assigned to one of three groups: placebo; lorundrostat 50 mg once daily; or lorundrostat 50 mg once daily with the option to increase to 100 mg at week six. The primary endpoint was change from baseline in systolic blood pressure at six weeks versus placebo, measured by automated office blood pressure monitoring.

About Hypertension

Having sustained, elevated blood pressure (or hypertension) (BP) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertension patients achieve their BP goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat

Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as CKD and OSA. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in hypertensive participants.

The Company has now completed four successful clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The Company has completed two pivotal, registrational trials, including the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic BP by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit

https://mineralystx.com. Follow Mineralys on

LinkedIn,

Twitter and Bluesky.

Forward Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Company’s expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Company’s expectation that Advance-HTN and Launch-HTN may serve as pivotal trials in submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA); the anticipated timing of NDA submission and the FDA’s review of the same; the Company’s ability to evaluate lorundrostat as a potential treatment for CKD, OSA, uHTN or rHTN; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of participants in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; any delays in the FDA’s review of our planned NDA submission, including as a result of a government shutdown or reductions in agency funding or personnel, the results of our clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for an NDA submission or regulatory approval of lorundrostat; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for a local and/or global economic recession; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: [email protected]

China continues to leverage its near-monopoly on processing through export controls, even as it signals a temporary pause on new restrictions. Now a second rival has joined the field: Russia, with President Vladimir Putin ordering a national strategy to develop the country's vast reserves.

, /PRNewswire/ -- Lennar Corporation (NYSE: LEN and LEN.B) ("Lennar") announced today that in view of the continuation of the government shutdown, during which the Securities and Exchange Commission ("SEC") will not declare registration statements effective, Lennar is further extending the expiration date for its previously announced offer to exchange the approximately 20% it owns of the total outstanding shares of Millrose Properties, Inc. (NYSE: MRP) ("Millrose") for outstanding shares of Lennar Class A common stock (the "Exchange Offer"). In anticipation that the shutdown may end shortly, the Exchange Offer, which had been scheduled to expire at 12:00 midnight, New York City time, on November 14, 2025, is being extended to expire at 12:00 midnight, New York City time, on November 21, 2025 (the "Expiration Date"). 

The Exchange Offer cannot be completed until the registration statement on Form S-4 filed by Millrose with the SEC in connection with the Exchange Offer (the "Registration Statement") is declared effective, and during the current U.S. federal government shutdown the SEC is not declaring registration statements effective. The potential for this additional extension was anticipated in Lennar's press release issued on October 31, 2025 and in the Registration Statement. 

If the SEC does not declare the Registration Statement effective by the Expiration Date, Lennar will have to further extend the Exchange Offer or terminate it without accepting tendered shares.

If the shutdown is still in effect on November 14, 2025, Lennar will announce by 11:59 p.m. on November 14, 2025 whether it will (1) further extend the Exchange Offer and, if so, the further extended expiration date, or (2) terminate the Exchange Offer.

All other terms, provisions and conditions of the Exchange Offer will remain in full force and effect. Lennar reserves the right to terminate, withdraw, amend or further extend the Exchange Offer at any time.

About Lennar
Lennar Corporation, founded in 1954, is one of the nation's leading builders of quality homes for all generations. Lennar builds affordable, move-up and active adult homes primarily under the Lennar brand name. Lennar's Financial Services segment provides mortgage financing, title and closing services primarily for buyers of Lennar's homes and, through LMF Commercial, originates mortgage loans secured primarily by commercial real estate properties throughout the United States. Lennar's Multifamily segment is a nationwide developer of high-quality multifamily rental properties. LENX drives Lennar's technology, innovation and strategic investments. 

Forward-Looking Statements
This communication contains certain statements about Lennar and Millrose that are forward-looking statements. Forward-looking statements are based on current expectations and assumptions regarding Lennar's and Millrose's respective businesses, the economy and other future conditions. In addition, the forward-looking statements contained in this communication may include statements about the expected effects on Lennar and Millrose of the Exchange Offer, the anticipated timing and benefits of the Exchange Offer, Lennar's and Millrose's anticipated financial results, and other statements that are not historical facts.

Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and are detailed more fully in Lennar's and Millrose's respective periodic reports filed from time to time with the SEC, the Registration Statement relating to the Exchange Offer and the Prospectus forming a part of it, the Schedule TO and other Exchange Offer documents filed by Lennar or Millrose, as applicable, with the SEC. Additionally, the possibility that the ongoing U.S federal government shutdown will cause the SEC not to be able to declare the Registration Statement effective before the expected expiration of the Exchange Offer may cause the anticipated timing and completion of the Exchange Offer to differ materially from what is described in this press release. Such uncertainties, risks and changes in circumstances could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Lennar nor Millrose undertakes any obligation to update publicly such statements to reflect subsequent events or circumstances, except to the extent required by applicable securities laws. Investors should not put undue reliance on forward-looking statements.

Additional Information and Where to Find It
This communication is for informational purposes only and is not an offer to sell or exchange, a solicitation of an offer to buy or exchange any securities and a recommendation as to whether investors should participate in the Exchange Offer. Millrose has filed with the SEC a Registration Statement on Form S-4 that includes the Prospectus. The Exchange Offer is made solely by the Prospectus. The Prospectus contains important information about the Exchange Offer, Lennar, Millrose and related matters, and Lennar will deliver the Prospectus to holders of Lennar Class A common stock. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING ANY INVESTMENT DECISION, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. None of Lennar, Millrose or any of their respective directors or officers or the dealer managers appointed with respect to the Exchange Offer makes any recommendation as to whether you should participate in the Exchange Offer.

Lennar has filed with the SEC a Schedule TO, as amended on November 5, 2025, which contains important information about the Exchange Offer.

Holders of Lennar Class A common stock may obtain copies of the Prospectus, the Registration Statement, the Schedule TO and other related documents, and any other information that Lennar and Millrose file electronically with the SEC free of charge at the SEC's website at http://www.sec.gov. Holders of Lennar Class A common stock will also be able to obtain a copy of the Prospectus by clicking on the appropriate link on www.envisionreports.com/lennarexchange.

Lennar has retained Georgeson LLC as the information agent for the Exchange Offer. To obtain copies of the Prospectus and related documents, or for questions about the terms of the Exchange Offer or how to participate, you may contact the information agent at +1 (888) 624-7035 (toll-free for stockholders, banks and brokers) or +1 (218) 209-2908 (all others outside the United States and Canada).

Contact:
Ian Frazer
Investor Relations
Lennar Corporation
(305) 485-4129

SOURCE Lennar Corporation

Q3: 2025-11-06 Earnings SummaryEPS of $0.09 misses by $0.02

 |

Revenue of

$3.30M

(2,927.52% Y/Y)

beats by $600.00K

Cherry Hill Mortgage Investment Corporation (CHMI) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST

Company Participants

Jeffrey Lown - President, CEO & Director
Julian Evans - Chief Investment Officer
Apeksha Patel - CFO, Controller, Treasurer & Secretary

Conference Call Participants

Garrett Edson - ICR Inc.
Timothy D'Agostino - B. Riley Securities, Inc., Research Division
Mikhail Goberman - Citizens JMP Securities, LLC, Research Division

Presentation

Operator

Good day, and welcome to Cherry Hill Mortgage Investment Corporation's Third Quarter 2025 Conference Call. [indiscernible] I would now like to turn the call over to Garrett Edson of ICR. Please go ahead.

Garrett Edson
ICR Inc.

We'd like to thank you for joining us today for Cherry Hill Mortgage Investment Corporation's Third Quarter 2025 Conference Call. In advance of this call, we issued a press release that was distributed earlier this afternoon. That press release and our third quarter 2025 investor presentation have been posted to the Investor Relations section of our website at www.chmireit.com. On today's call, management's prepared remarks and answers to your questions may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ from those discussed today. Examples of forward-looking statements include those related to interest income, financial guidance, IRRs, future expected cash flows as well as prepayment and recapture rates, delinquencies and non-GAAP financial measures such as earnings available for distribution or EAD and comprehensive income.

Forward-looking statements represent management's current estimates, and Cherry Hill assumes no obligation to update any forward-looking statements in the future. We encourage listeners to review the more detailed discussions related to these forward-looking statements contained in the company's filings with the SEC and the definitions contained in the financial presentations available on the company's website. Today's conference call is hosted by Jay Lown, President and CEO; Julian Evans, the Chief Investment Officer; and

Recommended For You

Q3: 2025-11-06 Earnings SummaryEPS of -$1.10 misses by $0.93

 |

Revenue of

$422.60M

(-5.84% Y/Y)

misses by $34.08M

Alta Equipment Group Inc. (ALTG) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST

Company Participants

Jason Dammeyer - Director of SEC Reporting & Technical Accounting
Ryan Greenawalt - CEO & Chairman
Anthony Colucci - Chief Financial Officer

Conference Call Participants

Liam Burke - B. Riley Securities, Inc., Research Division
Steven Ramsey - Thompson Research Group, LLC

Presentation

Operator

Good afternoon, and thank you for attending the Alta Equipment Group Third Quarter 2025 Earnings Conference Call. My name is Harry, and I'll be your moderator for today's call. I will now turn the call over to Jason Dammeyer, Vice President of Accounting and Reporting with Alta Equipment Group. Please go ahead.

Jason Dammeyer
Director of SEC Reporting & Technical Accounting

Thank you, Harry. Good afternoon, everyone, and thank you for joining us today. A press release detailing Alta's third quarter 2025 financial results was issued this afternoon and is posted on our website, along with the presentation designed to assist you in understanding the company's results. On the call with me today are Ryan Greenawalt, our Chairman and CEO; and Tony Colucci, our Chief Financial Officer. For today's call, management will first provide a review of our third quarter 2025 financial results. We will begin with some prepared remarks before we open the call for your questions. Please proceed to Slide 2.

Before we get started, I'd like to remind everyone that this conference call may contain certain forward-looking statements, including statements about future financial results, our business strategy and financial outlook, achievements of the company and other nonhistorical statements as described in our press release. These forward-looking statements are subject to both known and unknown risks, uncertainties and assumptions, including those related to Alta's growth, market opportunities and general economic and business conditions.

We have based these forward-looking statements

Recommended For You

ViaSat (VSAT - Free Report) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to a loss of $1.07 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +181.82%. A quarter ago, it was expected that this provider of satellite and wireless networking technology would post a loss of $0.05 per share when it actually produced earnings of $0.17, delivering a surprise of +440%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

ViaSat, which belongs to the Zacks Wireless Equipment industry, posted revenues of $1.14 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.68%. This compares to year-ago revenues of $1.12 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

ViaSat shares have added about 317% since the beginning of the year versus the S&P 500's gain of 14.3%.

What's Next for ViaSat?While ViaSat has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for ViaSat was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.84 on $1.17 billion in revenues for the coming quarter and $1.69 on $4.67 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Wireless Equipment is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Computer and Technology sector, Semtech (SMTC - Free Report) , has yet to report results for the quarter ended October 2025.

This chipmaker is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +69.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Semtech's revenues are expected to be $266.65 million, up 12.6% from the year-ago quarter.

November 07, 2025 6:23 PM EST | Source: Solution Financial Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2025) - Solution Financial Inc. (TSX: SFI) (the "Company" or "Solution"), a leading provider of luxury automotive and yacht leasing in British Columbia, is pleased to announce that the Company's Board of Directors has authorized the payment of a quarterly dividend of $0.001. The quarterly dividend is payable on December 15, 2025 to common shareholders of record as of the close of business on November 28, 2025. This dividend is a "non-eligible dividend" for Canadian income tax purposes.

About Solution

Solution Financial was incorporated under the provisions of the Business Corporations Act (British Columbia) in 2004 and specializes in sourcing and leasing luxury and exotic vehicles, yachts and other high value assets. Solution works with a select group of automotive and marine dealerships providing lending solutions to clients who cannot obtain leasing terms with traditional Canadian financial institutions or other sub-prime lenders. Typical customers include new immigrants, business owners and international students. Solution provides a unique leasing experience whereby it partners with its clients to help them navigate the challenges of acquiring, insuring, maintaining and upgrading vehicles and luxury assets in Canada.

For further information, please contact Sean Hodgins at (778) 318-1514.

ON BEHALF OF THE BOARD

(signed) "Bryan Pang"
Bryan Pang
President, CEO and Director

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273723

In brief
Zcash surged 33% on Friday to a recent high of nearly $735, triggering $51 million in short liquidations and ranking third in crypto liquidations behind Bitcoin and Ethereum.
The token’s price has jumped tenfold in five weeks amid growing privacy concerns about Bitcoin’s centralization and corporate influence.
Thursday’s harsh sentence for a Bitcoin privacy app developer may have further fueled Zcash’s rally.
Privacy-focused Bitcoin alternative Zcash went on a tear Friday, surging some 33% in a matter of hours and triggering over $51 million in short position liquidations.

The token surged to nearly $735 Friday afternoon, up from $536 just a day earlier. It has since settled to $666 as of this writing, still up 25% over the past day.

That rapid price action made Zcash-related positions the third-most liquidated in crypto on Friday, behind only dominant mainstays Bitcoin and Ethereum. Over $59 million worth of Zcash positions have been liquidated, including longs, per data from CoinGlass, compared to $150 million in liquidations for BTC and $146 million for ETH.

Zcash, until recently a fairly obscure cryptocurrency, has been on a near-nonstop streak for over a month. The token, which had hovered around $40 for over three years, began pumping in early October and hasn’t let up since. In just five weeks, its price has ballooned by a factor of 10.

According to data from CoinGecko, Friday's peak was the highest price registered since January 2018. Even so, at its current price, Zcash remains 79% below the all-time high mark of $3,191 set back in 2016.

Analysts have argued in recent weeks that Zcash’s recent rally is thanks in large part to growing anxieties about Bitcoin’s privacy and decentralization in a moment of unprecedented corporate and political embrace of the world’s top cryptocurrency. 

Zcash, created in 2016 via a fork of Bitcoin’s codebase, encourages anonymous transactions with a system of zero-knowledge proofs. It is the largest privacy focused crypto token by market capitalization, with a current valuation of about $11 billion.

Though Zcash has consistently climbed in price for the last several weeks, today’s surge could have been at least in part influenced by the outcome of a closely watched trial in the United States pertaining to privacy and crypto software development. 

On Thursday, Keonne Rodriguez, a developer of the privacy-focused Bitcoin app Samourai Wallet, was sentenced to five years in federal prison, after he pled guilty to operating an unlicensed money transmitter. 

That sentence—the maximum possible Rodriguez could have received—was requested by President Trump's Department of Justice, which has in other contexts pledged to protect the rights of crypto developers.

The decision was roundly criticized by leading crypto and privacy advocates.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

The cryptocurrency has hovered around the $100K threshold for multiple days in a row, with no clear sign of an imminent rally. Bitcoin Stalls at $100K, Have We Reached a New Plateau? November is typically a good month for bitcoin.

Bit Digital now holds 153,546 ETH, a massive bet positioning the public company as a cornerstone of the institutional digital asset landscape far beyond its mining origins.

Summary

Bit Digital boosted its Ethereum holdings to 153,546 ETH, valued at $590.5 million as of October 31.
Around 86% of its ETH is staked, generating yield as the company pivots from Bitcoin mining to Ethereum-native finance.

In a press release dated Nov. 7, Nasdaq-listed Bit Digital announced that its Ethereum (ETH) treasury had grown to approximately 153,547 ETH, valued at about $590.5 million as of October 31.

The company said it acquired over 31,000 ETH during the month, pushing its average cost basis to $3,045 per token. Bit Digital also reported that roughly 86% of its holdings, about 132,480 ETH, were staked, generating 249 ETH in monthly rewards at an annualized yield of 2.93 percent. The disclosure marks another step in the firm’s ongoing transition from Bitcoin mining to Ethereum-native yield operations.

Bit Digital’s shift toward Ethereum-native finance
Bit Digital began accumulating Ethereum in 2022, marking a quiet but deliberate pivot away from its legacy as one of North America’s largest Bitcoin miners. The scale of its commitment became undeniable earlier this year when the company executed a complete swap of its Bitcoin treasury for Ethereum. This move signaled a fundamental belief in Ethereum’s distinct value proposition.

According to CEO Sam Tabar, the decision to pivot was driven by a conviction in Ethereum’s superior utility as a foundational technology. Tabar has publicly framed the shift around Ethereum’s role as a core settlement layer for the next generation of finance, specifically highlighting the growth of tokenized real-world assets and stablecoins.

He has argued that while Bitcoin functions primarily as a store of value, Ethereum’s programmable nature and robust ecosystem position it to capture the economic activity of widespread asset tokenization, making its native asset, ETH, a compelling yield-bearing instrument.

The move also situates Bit Digital among a growing list of public companies making long-term commitments to Ethereum. BitMine Immersion Tech, for instance, recently disclosed holdings of 3.31 million ETH valued at roughly $13.3 billion, while SharpLink Gaming’s Ethereum balance climbed to 859,853 ETH following its latest purchase.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Dogecoin has spent the past week hovering between $0.15 and $0.17, which is an extension of its lost momentum in October. Despite the overall weakness across the crypto market, technical analysis shows that the meme coin has maintained a firm footing near its support zone and resisted the broader bearish pressure by holding above $0.15. 

Bitcoin’s recent price movements have set the tone for the rest of the market, but Dogecoin’s price action suggests that the token might be preparing for a reversal phase. A technical analysis from crypto analyst NekoZ on X has drawn considerable interest, as it points to a bullish setup forming on Dogecoin’s weekly chart.

Symmetrical Triangle Points To A Bullish Bounce
According to NekoZ, Dogecoin is currently trading within a massive symmetrical triangle pattern that has been forming for months. This pattern is visible on the weekly candlestick price chart, and the formation goes as far back as late 2024.

The weekly chart shows the price approaching the lower boundary of this structure, where there is a high possibility of a reversal. The price action within the triangle shows the creation of higher highs in October, and Dogecoin could undergo an explosive move in either direction. Given that the current structure has defended above $0.15, the setup is tilting toward a bullish breakout scenario. 

Source: Chart from NekoZ on X
The analyst’s chart highlights that a successful bounce from the current zone could drive Dogecoin’s price back towards the upper trendline. A sustained move above $0.18 could be the first sign of this possibility, especially if it is accompanied by an increase in trading volume. 

New Impulse Wave Could Push DOGE To $0.35
Dogecoin’s price is hovering right within the circled region on the chart, which means that it is testing the lower support line of the triangle. The past few weekly candles show that buyers have defended the lower range, preventing a deeper correction.

If Dogecoin manages to bounce at the lower trendline, then the next outlook would be a push upwards. However, the meme coin still has a long climb ahead before testing the resistance area between $0.30 and $0.33.

A break above the upper trendline will effectively almost double its current value. Such a move would mark the start of a new impulse wave and signify the eventual break of the symmetrical triangle formation that has characterized Dogecoin’s price action since the beginning of the year. It would also open the path for a Dogecoin price outlook at $0.35 and above.

However, the symmetrical triangle’s completion move also depends on how fast Bitcoin can stabilize above $100,000 and the broader market sentiment turns risk-on again. At the time of writing, Dogecoin is trading at $0.1643, up by 0.5% in the past 24 hours.

DOGE trading at $0.16 on the 1D chart | Source: DOGEUSDT on Tradingview.com
Featured image from Getty Images, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Charles Edwards, founder of Capriole Investments, has identified a concerning trend in the Bitcoin (BTC) and broader cryptocurrency market that adds to the ongoing sentiment of bearishness among investors. 

Over 1 Million BTC Sold By OG Investors Since June
In a recent post on the social media platform X (formerly Twitter), Edwards highlighted that “OG” Bitcoin whales are actively cashing out their holdings.

Accompanying his remarks was a chart illustrating the extent of this phenomenon, showing on-chain spending from “OG” Bitcoin holders—those who have held their assets for over seven years. 

The chart prominently features two color-coded categories: orange for $100 million dumps and red for $500 million dumps, vividly demonstrating the scale of liquidations by these long-term investors. 

OG whale activity over the years. Source: Charles Edwards on X
Notably, the chart reveals that OG Bitcoin whales have been offloading their assets continuously since November 2024, which helps explain Bitcoin’s underperformance compared to other risk assets throughout 2025.

Despite this selling pressure, the market has exhibited unusual resilience, absorbing these large sell-offs without experiencing the drastic price declines typically seen in previous cycles. 

This behavior represents a new pattern for the market, as Wall Street analysts have noted that the net sales from long-term holders have surpassed 1 million Bitcoin since late June, according to research from Compass Point analyst Ed Engel.

Potential Liquidations Driving Bitcoin To $70,000
A significant liquidation of leveraged crypto positions on October 10 further compounded the market’s struggles, with Bitcoin failing to regain critical support levels of $117,000 and then $112,000. 

Markus Thielen, founder and CEO of Singapore-based 10X Research, expressed his concerns in an interview with Yahoo Finance, noting that the inability to reclaim these levels suggests that the market may indeed be in a bear cycle. 

His firm, which had previously predicted Bitcoin would fall to $100,000, now believes the market could be “a few weeks away” from finding a buyable bottom.

Thielen also warned of a potential correction that could see Bitcoin prices decline further, citing the recent strength of the US dollar as an additional challenge for the crypto markets. 

He mentioned an “air pocket” below $93,000, indicating a lack of support that could lead to further liquidations, possibly driving prices down to the $70,000 range.

The daily chart shows BTC’s price struggling to consolidate above the $100,000 mark. Source: BTCUSDT on TradingView.com
Featured image from DALL-E, chart from TradingView.com 

JPMorgan's IBIT stake, valued at about $333 million at the end of the quarter and around $312 million today, is up 64% from June.

Bitcoin price reached $103,500 today after a week of tumultuous trading. Bitcoin started the day down close to $100,000 but rebounded throughout market trading to highs of $103,859 today. 

Earlier this week, Bitcoin plunged below $100,000 for the first time since June on November 4. 

The slump came amid macro pressures, political headlines, and fading risk appetite, pushing bitcoin down to $99,070 and more than 20% off its October high of $126,000, technically entering a bear phase. 

The sell-off follows October’s massive liquidation events, a series of hacks, and trade tensions with China. 

The Federal Reserve’s hawkish tone, including a modest rate cut and signals that further cuts may not come, weighed on sentiment. 

During the Fed’s most recent press conference, Jerome Powell said that December’s rate cuts aren’t guaranteed, Bitcoin’s price immediately reacted — plunging to $109,000 on the day. Since then, the price continued bleeding into this week. The broader crypto market reacted similarly. 

Powell said that inflation excluding the impact of tariffs is “not so far” from the central bank’s 2% target, but emphasized that policymakers have “not made a decision about December.” Powell noted that officials held “strongly differing views” during today’s meeting.

A stronger U.S. dollar added pressure. Technical charts show Bitcoin struggling around its 200-day moving average, with support near $96,000, according to Bitcoin Magazine Pro data.  

Despite this, some bulls, including Michael Saylor’s firm, continue buying the dip, signaling cautious confidence.

Bitcoin price technical analysis
Despite the volatility, major institutions like JPMorgan remain bullish, forecasting a potential rise to $170,000 within 6–12 months, citing undervaluation relative to gold and the conclusion of heavy deleveraging.

Technical indicators offer mixed signals. Up to today, Bitcoin has been trading in a tight $100,000 –$102,000 support corridor, facing resistance at $106K–$114K. 

Short-term buyers have exhausted momentum, while on-chain data highlights friction between capitulating short-term holders at $107K–$110K and long-term holders defending $95K–$96K. 

Institutional flows show tentative accumulation: after six days of withdrawals totaling $2.05 billion, U.S. spot Bitcoin ETFs recorded $240 million in inflows, led by BlackRock and Fidelity. 

Whale activity indicates profit-taking rather than panic, with over 319,000 BTC reactivated in the past month, mostly held six to twelve months.

Recently, Cathie Wood lowered ARK Invest’s 2030 Bitcoin forecast from $1.5 million to $1.2 million, citing stablecoins increasingly taking on Bitcoin’s transactional role while reaffirming its long-term “digital gold” potential. 

Galaxy Digital also cut its year-end Bitcoin target from $185,000 to $120,000, pointing to whale selling, rotations into other assets, and leveraged liquidations, while describing the market as entering a “maturity era.” 

Micah Zimmerman

Micah first discovered Bitcoin in 2018 but remained a skeptic on the sidelines for too long. Since 2021, he has covered crypto and business and now works as a junior news reporter for Bitcoin Magazine, based in North Carolina.

Ethereum (ETH) price recorded a relief rally on Friday, November 7. The large-cap altcoin gained over 4% during the past 24 hours to retest a resistance/support level of around $3,468 during the mid-North American trading session. Notably, the ETH/USD pair retested a supply wall established during the last two days.

Bitcoin Magazine Mathematically Predicting Bitcoin Price Floor Data models suggest the next bitcoin price bear market may be shallower than past cycles, revealing how maturity is reshaping Bitcoin's volatility. Mathematically Predicting Bitcoin Price Floor Matt Crosby.